Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790816 · ClinicalTrials.gov registry record · Phase 1
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
NCT00790816: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT00790816 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 500 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (733% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00790816, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
Study Summary
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
Interventions
- DRUG Lapatinib
- DRUG Lapatinib in combination with an anti-cancer agent
- DRUG Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2008-10 |
| Est. Completion | 2016-08-19 |
| Phase | Phase 1 |
What the finished NCT00790816 record still lists
NCT00790816 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (733% higher).
The record links to 0 conditions, and to 3 interventions - of which Lapatinib is the first listed.
NCT00790816 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00790816 about?
NCT00790816 is a clinical study titled "Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents". This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
What is the current status of trial NCT00790816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 2008-10. Estimated completion is 2016-08-19.
What interventions are being tested in trial NCT00790816?
The interventions under investigation include: Lapatinib (DRUG), Lapatinib in combination with an anti-cancer agent (DRUG), Lapatinib in combination with an anti-cancer agent as specified by parent protocol (DRUG).
Who is sponsoring clinical trial NCT00790816?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00790816's enrollment target sits among peer trials
500 44th of 2000 higher than 1,955 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia